|
CA2344208A1
(en)
|
2001-04-30 |
2002-10-30 |
Oxford Biomedica (Uk) Limited |
Method
|
|
US9738907B2
(en)
|
2002-02-01 |
2017-08-22 |
Oxford Biomedica (Uk) Limited |
Viral vector
|
|
DK2348119T3
(en)
|
2002-02-01 |
2017-08-21 |
Oxford Biomedica (Uk) Ltd |
Polycistronic lentiviral vector
|
|
WO2003066810A2
(en)
*
|
2002-02-04 |
2003-08-14 |
Novartis Ag |
Recombinant bovine immunodeficiency virus based gene transfer system
|
|
WO2005118809A2
(en)
*
|
2004-04-29 |
2005-12-15 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for enhancing cell adhesion properties
|
|
TW200613554A
(en)
*
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
GB0526210D0
(en)
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Vectors
|
|
WO2009153563A1
(en)
|
2008-06-18 |
2009-12-23 |
Oxford Biomedica (Uk) Limited |
Virus purification
|
|
CN102946907A
(zh)
|
2010-05-28 |
2013-02-27 |
牛津生物医学（英国）有限公司 |
慢病毒载体向脑的递送
|
|
GB201118636D0
(en)
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
|
DK2986635T3
(en)
|
2013-04-18 |
2019-01-28 |
Fond Telethon |
EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
|
|
ES2747951T3
(es)
|
2013-10-24 |
2020-03-12 |
Ospedale San Raffaele Srl |
Método
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
PT3575315T
(pt)
|
2014-09-15 |
2022-12-16 |
Agc Biologics S P A |
Recetores de antigénios quiméricos
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
GB201519086D0
(en)
|
2015-10-28 |
2015-12-09 |
Syncona Partners Llp |
Gene Therapy
|
|
GB201604146D0
(en)
|
2016-03-10 |
2016-04-27 |
Nightstarx Ltd |
Prenylation assay
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
EP3235828A1
(en)
*
|
2016-04-21 |
2017-10-25 |
Genethon |
Stable pseudotyped lentiviral particles and uses thereof
|
|
EP3318285A1
(en)
|
2016-11-08 |
2018-05-09 |
Oxford University Innovation Limited |
Treatment of eye disease
|
|
CN109952377A
(zh)
|
2016-12-01 |
2019-06-28 |
雀巢产品技术援助有限公司 |
调节fam46a的方法
|
|
CN108130333A
(zh)
*
|
2016-12-01 |
2018-06-08 |
上海泽润生物科技有限公司 |
重组脊髓灰质炎ⅰ型病毒样颗粒
|
|
EP3375876A1
(en)
|
2017-03-13 |
2018-09-19 |
Evonetix Ltd |
Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures
|
|
EP3595705A1
(en)
|
2017-03-15 |
2020-01-22 |
Oxford BioMedica (UK) Limited |
Method
|
|
WO2018178247A1
(en)
|
2017-03-31 |
2018-10-04 |
Nestec S.A. |
Methods of modulating ank1
|
|
GB201706121D0
(en)
*
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Stable cell lines for retroviral production
|
|
DK3612624T3
(da)
|
2017-04-21 |
2024-12-09 |
Ospedale San Raffaele Srl |
Genterapi
|
|
EA201992536A1
(ru)
|
2017-04-24 |
2020-03-05 |
Оспедале Сан Раффаэле С.Р.Л. |
Tcr и пептиды
|
|
WO2019068854A1
(en)
|
2017-10-06 |
2019-04-11 |
Ospedale San Raffaele S.R.L. |
GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
|
|
AU2018352986A1
(en)
|
2017-10-17 |
2020-05-14 |
Nightstarx Limited |
Prenylation assay
|
|
US20200385736A1
(en)
|
2017-11-21 |
2020-12-10 |
Societe Des Produits Nestle S.A. |
Methods of modulating alk
|
|
GB201720948D0
(en)
|
2017-12-15 |
2018-01-31 |
Autolus Ltd |
Plasmid system
|
|
FI3633040T3
(fi)
|
2017-12-22 |
2023-08-03 |
Oxford Biomedica Ltd |
Retrovirusvektori
|
|
WO2019134866A1
(en)
|
2018-01-03 |
2019-07-11 |
Molmed Spa |
Chimeric antigen receptors containing optimal spacer region
|
|
US12227756B2
(en)
|
2018-04-18 |
2025-02-18 |
Ucl Business Ltd |
Engineered regulatory T cell
|
|
CN112367973A
(zh)
|
2018-05-15 |
2021-02-12 |
旗舰先锋创新V股份有限公司 |
融合剂脂质体组合物和其用途
|
|
US20210095288A1
(en)
|
2018-05-17 |
2021-04-01 |
Societe Des Produits Nestle S.A. |
Methods of modulating nkx6.3
|
|
US12304962B2
(en)
|
2018-05-30 |
2025-05-20 |
Glycostem Therapeutics B.V. |
CAR NK cells
|
|
CA3105953A1
(en)
|
2018-07-09 |
2020-01-16 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
|
GB201814203D0
(en)
|
2018-08-31 |
2018-10-17 |
King S College London |
Engineered regulatory t cell
|
|
GB201817821D0
(en)
|
2018-10-31 |
2018-12-19 |
Ospedale San Raffaele Srl |
TCR and peptides
|
|
US20230048166A1
(en)
|
2018-11-14 |
2023-02-16 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
|
EP3880179A2
(en)
|
2018-11-14 |
2021-09-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for cns delivery
|
|
WO2020102503A2
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for t cell delivery
|
|
CA3124039A1
(en)
|
2018-12-19 |
2020-06-25 |
King's College London |
Immunotherapeutic methods and compositions
|
|
GB201900687D0
(en)
|
2019-01-17 |
2019-03-06 |
King S College London |
Immunotherapeutic methods and compositions
|
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
CN115835887A
(zh)
|
2019-03-10 |
2023-03-21 |
牛津生物医学（英国）有限公司 |
用于治疗帕金森病的基因治疗组合物和方法
|
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
|
GB201907493D0
(en)
|
2019-05-28 |
2019-07-10 |
Ospedale San Raffaele |
Agents and methods for treating viral infections
|
|
GB201912515D0
(en)
|
2019-08-30 |
2019-10-16 |
King S College London |
Engineered regulatory T cell
|
|
EP4025698A1
(en)
|
2019-09-03 |
2022-07-13 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
|
WO2021094752A1
(en)
|
2019-11-12 |
2021-05-20 |
Oxford Biomedica (Uk) Limited |
Production system
|
|
US20240052366A1
(en)
|
2020-02-13 |
2024-02-15 |
Oxford Biomedica (Uk) Limited |
Production of Lentiviral Vectors
|
|
US20230138428A1
(en)
|
2020-02-25 |
2023-05-04 |
Quell Therapeutics Limited |
Chimeric receptors for use in engineered cells
|
|
WO2021181108A1
(en)
|
2020-03-13 |
2021-09-16 |
Oxford Biomedica (Uk) Limited |
Lentiviral vectors
|
|
AU2021248815A1
(en)
|
2020-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Targeted lipid particles and compositions and uses thereof
|
|
GB202007169D0
(en)
|
2020-05-14 |
2020-07-01 |
Ospedale San Raffaele Srl |
Epidermal growth factor receptor
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
GB202013477D0
(en)
|
2020-08-27 |
2020-10-14 |
Quell Therapeutics Ltd |
Nucleic acid constructs for expressing polypeptides in cells
|
|
WO2022047316A1
(en)
|
2020-08-28 |
2022-03-03 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
|
CN114181954A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏浦珠生物医药科技有限公司 |
优化的慢病毒包装系统
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
GB202018657D0
(en)
|
2020-11-26 |
2021-01-13 |
Ospedale San Raffaele Srl |
Agents and methods for increasing liver immune response
|
|
CN112430582B
(zh)
*
|
2020-12-04 |
2022-05-03 |
北京艺妙神州医药科技有限公司 |
一种慢病毒稳定包装细胞系及其制备方法
|
|
EP4267601A1
(en)
|
2020-12-23 |
2023-11-01 |
Quell Therapeutics Limited |
Inducible signalling protein
|
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
|
MX2023009036A
(es)
|
2021-02-01 |
2023-10-30 |
Epsilen Bio S R L |
Silenciamiento de genes.
|
|
CA3207426A1
(en)
|
2021-02-15 |
2022-08-18 |
Vania Broccoli |
Epigenetic silencing for treatment of cancer
|
|
GB202102637D0
(en)
|
2021-02-24 |
2021-04-07 |
Quell Therapeutics Ltd |
Engineered regulatory t cell
|
|
GB202102832D0
(en)
*
|
2021-02-26 |
2021-04-14 |
Ip2Ipo Innovations Ltd |
Retroviral vectors
|
|
CN117377771A
(zh)
|
2021-05-12 |
2024-01-09 |
特莱索恩基金会 |
载体系统
|
|
IL308836A
(en)
|
2021-05-28 |
2024-01-01 |
Sana Biotechnology Inc |
Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
TW202321286A
(zh)
|
2021-09-21 |
2023-06-01 |
英商圭爾醫療有限公司 |
抗p75ntr嵌合抗原受體
|
|
WO2023047100A1
(en)
|
2021-09-21 |
2023-03-30 |
Quell Therapeutics Ltd |
Anti-trem2 chimeric antigen receptor
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
WO2023077107A1
(en)
|
2021-10-29 |
2023-05-04 |
Sana Biotechnology, Inc. |
Methods and reagents for amplifying viral vector nucleic acid products
|
|
GB202117298D0
(en)
|
2021-11-30 |
2022-01-12 |
Quell Therapeutics Ltd |
Signalling protein
|
|
GB202117844D0
(en)
|
2021-12-09 |
2022-01-26 |
Oxford Biomedica Ltd |
Purification method
|
|
WO2023114949A1
(en)
|
2021-12-16 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4453022A1
(en)
|
2021-12-22 |
2024-10-30 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
MX2024008495A
(es)
|
2022-01-05 |
2024-09-04 |
Gyala Therapeutics Sl |
Anticuerpos anti-cd84 y receptores de antigenos quimericos.
|
|
EP4209511A1
(en)
|
2022-01-05 |
2023-07-12 |
Gyala Therapeutics Sociedad Limitada |
Anti-cd84 antibodies amd chimeric antigen receptors
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
EP4269426A1
(en)
|
2022-04-29 |
2023-11-01 |
Ospedale San Raffaele S.r.l. |
Gene therapy
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
US20260000790A1
(en)
|
2022-07-08 |
2026-01-01 |
Ospedale San Raffaele S.R.L. |
Transgene cassettes
|
|
US20260027145A1
(en)
|
2022-07-27 |
2026-01-29 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
WO2024033544A1
(en)
|
2022-08-12 |
2024-02-15 |
Ospedale San Raffaele S.R.L. |
Deglycosylation of native glycoproteins expressed on a tumor cell surface
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
EP4590688A1
(en)
|
2022-09-21 |
2025-07-30 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
EP4615492A1
(en)
|
2022-11-08 |
2025-09-17 |
Ospedale San Raffaele S.r.l. |
Polynucleotide and vector
|
|
WO2024100294A1
(en)
|
2022-11-11 |
2024-05-16 |
Ospedale San Raffaele S.R.L. |
Cdh17 car
|
|
GB202217541D0
(en)
|
2022-11-24 |
2023-01-11 |
Quell Therapeutics Ltd |
Recombinant receptor
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024133472A1
(en)
|
2022-12-22 |
2024-06-27 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
EP4651887A1
(en)
|
2023-01-16 |
2025-11-26 |
Ospedale San Raffaele S.r.l. |
T-cell receptors
|
|
JP2026507781A
(ja)
|
2023-01-23 |
2026-03-06 |
メディツィニシェ ホゥーシュル ハノーファー |
キメラ抗原受容体
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
CN120787258A
(zh)
|
2023-02-07 |
2025-10-14 |
圭尔医疗有限公司 |
Treg细胞培养方法
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024175805A1
(en)
|
2023-02-24 |
2024-08-29 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024194223A2
(en)
|
2023-03-17 |
2024-09-26 |
Ospedale San Raffaele S.R.L. |
Gene therapy
|
|
WO2024194605A1
(en)
|
2023-03-17 |
2024-09-26 |
Quell Therapeutics Limited |
Treg therapy
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
WO2024194355A1
(en)
|
2023-03-20 |
2024-09-26 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
KR20260016905A
(ko)
|
2023-03-22 |
2026-02-04 |
오스페달레 산 라파엘 에스.알.엘. |
유전자 치료
|
|
WO2024194642A1
(en)
|
2023-03-22 |
2024-09-26 |
Quell Therapeutics Limited |
Engineered t regulatory cell
|
|
WO2024194649A1
(en)
|
2023-03-22 |
2024-09-26 |
Quell Therapeutics Limited |
Engineered t cells and uses thereof
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220597A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Digital droplet based assay for detecting replication competent lentiviral vector
|
|
GB202307366D0
(en)
|
2023-05-17 |
2023-06-28 |
Ospedale San Raffaele Srl |
Vector
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
CN121586727A
(zh)
|
2023-06-21 |
2026-02-27 |
圭尔医疗有限公司 |
组成型细胞因子受体
|
|
JP2026521998A
(ja)
|
2023-06-28 |
2026-07-03 |
オスぺダレ サン ラファエレ ソチエタ レスポンサビリタ リミテ |
Ｔ細胞受容体
|
|
WO2025032194A1
(en)
|
2023-08-08 |
2025-02-13 |
Ospedale San Raffaele S.R.L. |
T-cell receptors
|
|
IT202300022191A1
(it)
|
2023-10-24 |
2025-04-24 |
Fond Telethon Ets |
Mezzi e metodi per la modifica genetica di uba1
|
|
GB202316264D0
(en)
|
2023-10-24 |
2023-12-06 |
Ospendale San Raffaele S R L |
Gene therapy
|
|
WO2025109189A1
(en)
|
2023-11-24 |
2025-05-30 |
Ospedale San Raffaele S.R.L. |
Engineered regulatory t cells and uses thereof
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
EP4640830A1
(en)
|
2024-04-23 |
2025-10-29 |
Fondazione Telethon ETS |
Means and methods for safe and efficient gene editing in cells
|
|
US20260176598A1
(en)
|
2024-07-04 |
2026-06-25 |
Quell Therapeutics Limited |
Expression construct
|
|
WO2026027876A1
(en)
|
2024-07-29 |
2026-02-05 |
Quell Therapeutics Limited |
Chimeric antigen receptor
|
|
GB202411558D0
(en)
|
2024-08-06 |
2024-09-18 |
Quell Therapeutics Ltd |
Culture method
|
|
GB202415025D0
(en)
|
2024-10-11 |
2024-11-27 |
Ospedale San Raffaele Srl |
Cell
|
|
WO2026088097A1
(en)
|
2024-10-24 |
2026-04-30 |
Fondazione Telethon Ets |
Mutation-independent genome editing
|